Merck, known as MSD outside the United States and Canada, announced the FDA has approved Keytruda, Merck's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell lung cancer based on results from the KEYNOTE-407 trial.
Taiho Oncology, Inc. announced the FDA has accepted and granted priority review for the supplemental New Drug Application for Lonsurf (trifluridine/tipiracil, TAS-102) as a treatment for patients with previously treated, advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Genentech announced the randomized phase III CLL14 study, which evaluated fixed-duration Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (progression-free survival as assessed by investigator) compared to standard-of-care Gazyva plus chlorambucil.
TESARO Inc. announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc.
Cofactor Genomics has launched an RNA-based immune profiling kit developed for laboratories wishing to derive the immune composition of tumor samples.
Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology's second annual National Cancer Opinion Survey.
Research in the October 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network--identifies risk factors for chemotherapy-induced febrile neutropenia.
The California Breast Cancer Research Program has launched the Global Challenge to Prevent Breast Cancer, a competition designed to surface game-changing research ideas to advance breast cancer prevention.
Barry Kramer, NCI's cancer prevention expert and an advocate for rigorous science announced his intention to retire from the institute.
Adam Margolin has been recruited by the Icahn School of Medicine at Mount Sinai to lead a new initiative to accelerate the pace of therapeutic discovery through integration of large-scale data analysis and advanced genomic technologies.
